Gene vectors |
PAEA128-b-PS40: |
1. pDNA |
1. Cancer |
1. Bioreductively cleavable disulfide linkage between cSCKs and PNA: higher efficiency and lower toxicity than Lipofectamine or Arg9-PNA conjugates in Hela cells. |
34
–
37
|
|
1. cSCKs-S-S-PNA |
2. PNA |
2. Gene therapy (modulate incorrect splicing) |
2. cSCKs/oligonucleotide, PNA, or pDNA complexes: |
|
|
2. cSCKs complexes: phosphorothioate-2′-O-methyl oligonucleotides, PNA or pDNA |
3. Phosphorothioate, 2′-O-methyl oligonucleotides |
|
a. N/P ratio of 6:1 gave the highest transfection. |
|
|
3. cSCKs complexes: The shell composition (primary amine, tertiary amine, and carboxylic acid group ratios): |
|
|
b. Higher transfection, lower cytotoxicity, and lower materials used than most common transfection reagents. |
|
|
PAA- co-PAEDMA-b-PS |
|
|
3. Increasing the proportion of tertiary relative to primary amine reduced the cytotoxicity and increased transfection efficiency. |
|
|
PAA- co-PAEA-b-PS |
|
|
|
|
|
PAEA-co-PAEDMA-b-PS |
|
|
|
|
Chemotherapeutics |
Thermosensitive: |
Doxorubicin |
Cancer |
Tm of the core could be tuned (temperature) |
38,39
|
|
PAA-b-P(ODA-co-DA) |
|
|
|
|
|
pH-responsive: |
Doxorubicin |
Cancer |
1. Higher Tg and Tm and aromatic styrene core (π–π-stacking): higher loading capacity and slower release rate. |
38,39,48
|
|
PAA-b-PS |
|
|
2. Increasing PAA/PS ratio: smaller core volumes, lower loading capacity, and lower release rate and extent. |
|
|
|
|
|
3. Crosslinking: lower release rate. |
|
|
|
|
|
4. The release rate was higher at pH 5 vs. pH 7.4. |
|
Antimicrobial |
PAA-b-PS |
Antimicrobial agents (Ag+ and SCCs) |
Treatment of pulmonary and urinary tract infections |
1. Drugs could be loaded into the shell or the core of the nanoparticles. |
49
|
|
|
|
|
2. Sustained release over several days. |
|
|
|
|
|
3. High antimicrobial activities against Gram-negative bacteria. |
|
Templates for multifunctional SCKs |
PAA104-b-PpHS41
|
Amino-terminated pyrazine (bifunctional fluorophore and crosslinker) |
1. pH-sensors |
1. Fluoresce and swell at high pH. |
50
|
|
|
|
2. In vivo imaging |
2. Shrink and quenched at low pH. |
|
|
|
|
3. Fluorescence or confocal microscopy |
|
|
Multifunctional |
Folate-SCKs based on PAA93-b-PMA164
|
1. 64Cu (PET and radiotherapy) |
1. In vivo tracking and imaging |
1. Multifunctional nanotheranostics. |
62
|
|
|
2. Fluorescein thiosemicarbazide (fluorophore) |
2. Cancer |
2. Tumor accumulation (EPR). |
|
|
|
|
3. Theranostic applications |
3. Specific uptake in vitro and in vivo (active targeting). |
|